Shares of Geron Co. (NASDAQ:GERN) were up 2.3% during mid-day trading on Wednesday . The stock traded as high as $2.72 and last traded at $2.56. Approximately 1,251,372 shares were traded during mid-day trading, a decline of 55% from the average daily volume of 2,766,825 shares. The stock had previously closed at $2.62.
Several analysts have issued reports on GERN shares. Zacks Investment Research cut shares of Geron from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Geron in a research note on Friday, November 3rd. Stifel Nicolaus reissued a “hold” rating and issued a $2.50 price target on shares of Geron in a report on Friday, November 3rd. Finally, BidaskClub raised shares of Geron from a “sell” rating to a “hold” rating in a report on Wednesday, January 24th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Geron currently has a consensus rating of “Hold” and a consensus target price of $3.75.
The stock has a market capitalization of $410.82, a price-to-earnings ratio of -13.28 and a beta of 2.78.
Geron Company Profile
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.